On Wednesday, Shares of Eli Lilly and Co (NYSE:LLY), lost -1.25% to $86.70.
Boehringer Ingelheim and Eli Lilly and Companys (LLY) Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14 percent when added to standard of care, in patients with type 2 diabetes (T2D) at high risk of CV events. There was a 38 percent reduction in CV death, with no noteworthydifference in the risk of non-fatal heart attack or non-fatal stroke.
In addition, treatment with Jardiance resulted in a lower risk of all-cause mortality (32 percent reduction) and hospitalization for heart failure (35 percent reduction).
These results are both novel and exciting for the millions of people living with type 2 diabetes at risk for cardiovascular disease. Addressing the burden of cardiovascular events, counting death, is at the core of diabetes care, and until now no single diabetes medication has been associated with a reduction in mortality, said lead investigator of the trial Dr. Bernard Zinman , Director, Diabetes Centre, Mount Sinai Hospital; Senior Scientist, Lunenfeld Tanenbaum Research Institute, and Professor of Medicine, University of Toronto , Canada. In this study, empagliflozin was shown to prevent one out of three cardiovascular deaths.
Life expectancy of people with T2D at high CV risk is, on average, reduced by up to twelve years1 with about 50 percent of deaths in people with T2D caused by CV disease.2,3 The effect of Jardiance in this trial was observed on top of standard of care. This means the benefit was seen over and above other treatments patients were already receiving for diabetes and/or cardiovascular disease (such as blood pressure and cholesterol lowering-medications).
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products.
Shares of Baxter International Inc (NYSE:BAX), inclined 0.79% to $35.76, during its last trading session.
Baxter International, declared that it presented at the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2015 at 8:00 a.m. (ET).
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Finally, Spectra Energy Corp. (NYSE:SE), ended its last trade with -2.18% loss, and closed at $27.42.
Spectra Energy Corp, Chief Executive Officer Greg Ebel spoke at the Raymond James 11th Annual North American Equities Conference on Tuesday, September 22, 2015. Ebel also served as chief executive officer of Spectra Energy Partners (SEP).
Spectra Energy Corp, through its auxiliaries, owns and operates a portfolio of natural gas-related energy assets in North America. The company’s Spectra Energy Partners segment engages in the transmission, storage, and gathering of natural gas, in addition to transportation and storage of crude oil and natural gas liquids (NGLs) for customers in various regions of the midwestern, northeastern, and southeastern United States and Canada.
This article is published by www.stocksnewswire.com. The content included in this article is just for informational purposes only. Stocksnewswire.com takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.
Neither Stocksnewswire.com nor any of Stocksnewswire.com partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.
Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by Stocksnewswire.com.
Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.